Michael Jaglal, MD

Cancer Focus:
Brain Cancer, Leukemia

Dr. Jaglal completed his hematology/oncology fellowship at the University of South Florida and Moffitt Cancer Center. His research interests are in benign hematologic disorders: hemophilia, von Willebrand's disease, anemias, hemostasis and thrombosis disorders. Clinically, Dr. Jaglal is a hematologist/oncologist and member of Moffitt Medical Group in the Satellite and Community Oncology Department practicing at Tampa General Hospital and Moffitt international Plaza. The MMG faculty at TGH provides invaluable oncology services to the large patient population of this leading regional hospital.

Education & Training

Fellowship:

• Moffitt Cancer Center - Hematology/Oncology

Residency:

• University of Louisville - Internal Medicine

Medical School:

• St. George's University School of Medicine, Grenada, West Indies - MD

• Laber DA, Patel PC, Logothetis CN, Patel AK, Jaglal M, Haider M, Visweshwar N, Rajasekaran-Rathnakumar G, Eatrides J. Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study. Eur J Haematol. 2024 Mar.112(3):450-457. Pubmedid: 37984551.
• Shahzad M, Khalid MF, Amin MK, Basharat A, Ammad-Ud-Din M, Park R, Anwar I, Faisal MS, Jaglal M. Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 Jan. Pubmedid: 38342727.
• Shahzad M, Noor J, Khalid MF, Amin MK, Nadeem M, Basharat A, Jaglal M. CLO24-091: Outcomes With Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. J Natl Compr Canc Ne. 2024 Apr.22(2.5). Pubmedid: 38580292.
• Shahzad M, Amin MK, Khalid MF, Basharat A, Noor J, Abbas S, Anwar I, Ud-Din MA, Jaglal M. CLO24-054: Treatment Outcomes in VEXAS Syndrome in Patients With MDS: A Systematic Review. J Natl Compr Canc Ne. 2024 Apr.22(2.5). Pubmedid: 38580244.
• Shahzad M, Noor J, Khalid MF, Amin MK, Nadeem M, Basharat A, Jaglal M. CLO24-055: Outcomes With Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. J Natl Compr Canc Ne. 2024 Apr.22(2.5). Pubmedid: 38579835.
• Basrawala H, Finley K, Jaglal M, Mohanty BD. First description of atrial fibrillation and congenital thrombotic thrombocytopenic purpura treated by left atrial appendage occlusion. EJHaem. 2023 May.4(2):428-431. Pubmedid: 37206280. Pmcid: PMC10188452.
• Jordan A, Jain AG, Koipallil GK, Reddy M, Chakkoli S, Midha S, Phuoc V, Eatrides J, Erhardt C, Patel AK, Rico J, Visweshar N, Mhaskar R, Parikh N, Laber D, Jaglal M. Can we lower the platelet threshold of ≥ 50 × 109/L for performing a lumbar puncture safely in patients with hematological malignancies?. Ann Hematol. 2023 Mar.102(3):663-668. Pubmedid: 36534146.
• Ammad Ud Din M, Chowdhury M, Shahzad M, Liaqat H, Jaglal M. Increased risk of eclampsia and preeclampsia during delivery hospitalizations in women with beta-thalassemia; An analysis of the National Inpatient Sample database. Eur J Obstet Gynecol Reprod Biol X. 2023 Mar.17:100175. Pubmedid: 36590708. Pmcid: PMC9800251.
• Visweshwar N, Rico JF, Ayala I, Jaglal M, Laber DA, Ammad-Ud-Din M, Sokol L, Sotomayor E, Manoharan A. Insights into the Impact of Hesitancy on Cancer Care and COVID-19. Cancers (Basel). 2023 Jun.15(12). Pubmedid: 37370725. Pmcid: PMC10296298.
• Ammad Ud Din M, Mahmud A, Mostafa M, Shahzad M, Liaqat H, Pinilla-Ibarz J, Jaglal M. Risks and outcomes of hospitalizations in patients with chronic lymphocytic leukemia admitted with immune thrombocytopenia: an analysis of the National Inpatient Sample Database. Ann Hematol. 2023 Apr.102(4):889-895. Pubmedid: 36781419.
• Visweshwar N, Ayala I, Jaglal M, Killeen R, Sokol L, Laber DA, Manoharan A. Primary immune thrombocytopenia: a 'diagnosis of exclusion'?. Blood Coagul Fibrinolysis. 2022 Sep.33(6):289-294. Pubmedid: 35867940. Pmcid: PMC9415225.
• Abowali H, Pacifico A, Erdinc B, Elkholy K, Burkhanova U, Aroriode T, Watson A, Ahmed MF, Uwagbale E, Visweshwar N, Jaglal M. Assessment of Bleeding Risk in Hospitalized COVID-19 Patients: A Tertiary Hospital Experience during the Pandemic in a Predominant Minority Population-Bleeding Risk Factors in COVID-19 Patients. J Clin Med. 2022 May.11(10). Pubmedid: 35628881. Pmcid: PMC9145335.
• Farooq MZ, Daniyal M, Qasim P, Jamshed H, Memon SF, Salman Y, Sayeed BZ, Abbasi M, Jaglal M. An evaluation of the content of hematology and medical oncology fellowship websites. Ann Med Surg (Lond). 2022 Aug.80:104079. Pubmedid: 35846864. Pmcid: PMC9283496.
• Visweshwar N, Jaglal M, Patel A, Laber D, Sokol L. Should we integrate viscoelastic assays with standard coagulation screening?. J Clin Pathol. 2021 Mar.74(3):141-143. Pubmedid: 33436484.
• Baumann Kreuziger L, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Jaglal M, Houghton DE, Streiff MB, Gali R, Feng M, Simpson P, Billett HH. Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. Thromb Res. 2021 Jun.202:155-161. Pubmedid: 33862470.
• Logothetis CN, Patel A, Eatrides J, Jaglal M, Haider M, Visweshwar N, Laber DA. Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution. J Clin Med. 2021 Jul.10(15). Pubmedid: 34362201. Pmcid: PMC8347784.
• Houghton DE, Billett HH, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Feng M, Dasgupta M, Jaglal M, Streiff MB, Simpson P, Gali R, Baumann Kreuziger L. Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. Blood Adv. 2021 Jul.5(14):2807-2812. Pubmedid: 34264267. Pmcid: PMC8341352.
• Blanquicett CJ, Raavi T, Mirk A, Johnson TM, Jaglal M, Cartwright EJ. Outcomes using direct-acting antiviral hepatitis-C treatment in older versus younger Veterans. J Am Geriatr Soc. 2021 Dec.69(12):3602-3607. Pubmedid: 34499744.
• Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neurooncol. 2021 Apr.23(4):677-686. Pubmedid: 33173935. Pmcid: PMC8041351.
• Laber DA, Eatrides J, Jaglal MV, Haider M, Visweshwar N, Patel A. A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer. Med Oncol. 2020 Sep.37(10):95. Pubmedid: 32979106.
• Visweshwar N, Zhang Y, Joseph H, Jaglal M, Ayala I. Chronic pain in patients with hemophilia: is it preventable?. Blood Coagul Fibrinolysis. 2020 Sep.31(6):346-352. Pubmedid: 32815911.
• Desai R, Koipallil GK, Thomas N, Mhaskar R, Visweshwar N, Laber D, Patel A, Jaglal M. Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. Sci Rep. 2020 Nov.10(1):18945. Pubmedid: 33144679. Pmcid: PMC7642281.
• Tebbi CK, Badiga A, Sahakian E, Arora AI, Nair S, Powers JJ, Achille AN, Jaglal MV, Patel S, Migone F. Plasma of Acute Lymphoblastic Leukemia Patients React to the Culture of a Mycovirus Containing Aspergillus flavus. J Pediat Hematol Onc. 2020 Jul.42(5):350-358. Pubmedid: 32576782.
• Patell R, Midha S, Kimani S, Martin R, Neparidze N, Jaglal M, Freed J, Key NS. Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States. Thromb Haemostasis. 2020 Dec.120(12):1725-1732. Pubmedid: 32828072. Pmcid: PMC7869034.
• Visweshwar N, Zhang Y, Joseph H, Jaglal M, Ayala I. Chronic pain in patients with hemophilia: is it preventable?. Blood Coagul Fibrinolysis. 2020 Aug.31(6):346-352. Pubmedid: 32804455.
• Mirza AS, Chen L, Amirzadeh S, Majethia S, Joppen J, Mirza S, Mhaskar R, Jaglal M, Ashraf N. Health disparities and chronic disease associated with anemia in free clinics: A retrospective study of uninsured patients in Tampa Bay. Postgrad Med. 2019 Sep.131(8):612-618. Pubmedid: 31524033.
• Visweshwar N, Jaglal M, Sokol L, Djulbegovic B. Hematological Malignancies and Arterial Thromboembolism. Indian J Hematol Blood Transfus. 2019 Oct.35(4):611-624. Pubmedid: 31741612. Pmcid: PMC6825093.
• Ashraf N, Visweshwar N, Jaglal M, Sokol L, Laber D. Evolving paradigm in thrombophilia screening. Blood Coagul Fibrinolysis. 2019 Jul.30(5):249-252. Pubmedid: 31145103. Pmcid: PMC6687403.
• Mirza AS, Yun S, Ali NA, Shin H, O'Neil JL, Elharake M, Schwartz D, Robinson K, Nowell E, Engle G, Badat I, Brimer T, Kuc A, Sequeira A, Mirza S, Sikaria D, Vera JD, Hackney N, Abusrur S, Jesurajan J, Kuang J, Patel S, Khalil S, Bhaskar S, Beard A, Abuelenen T, Ratnasamy K, Visweshwar N, Komrokji R, Jaglal M. Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience. Thromb J. 2019 Jul.17:13. Pubmedid: 31303864. Pmcid: PMC6604148.
• Mirza AS, Pabbathi S, Lu Y, Ayoubi N, Ewing A, Jaglal M, Roetzheim R. Comorbidities, risk, and socioeconomic factors of uninsured cancer survivors. Medicine. 2018 Nov.97(47):e13121. Pubmedid: 30461610. Pmcid: PMC6393034.
• Kerr D, Laber D, Visweshwar N, Jaglal M. Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin. Anticancer Res. 2018 Mar.38(3):1711-1713. Pubmedid: 29491106.
• Chaudhury A, Balakrishnan A, Thai C, Holmstrom B, Nanjappa S, Ma Z, Jaglal MV. The Efficacy and Safety of Rivaroxaban and Dalteparin in the Treatment of Cancer Associated Venous Thrombosis. Indian J Hematol Blood Transfus. 2018 Jul.34(3):530-534. Pubmedid: 30127566. Pmcid: PMC6081306.
• Visweshwar N, Jaglal M, Sokol L, Zuckerman K. Chemotherapy-related anemia. Ann Hematol. 2018 Feb.97(2):375-376. Pubmedid: 29103107.
• Laber DA, Chen MB, Jaglal M, Patel A, Visweshwar N. Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2018 Dec.16(6):473-481. Pubmedid: 30072309.
• Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Nov.123(22):4411-4418. Pubmedid: 28749548.
• Sandoval-Sus JD, Mogollon-Duffo F, Patel A, Visweshwar N, Laber DA, Kim R, Jaglal MV. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. J Immunother Cancer. 2017 Jun.5:49. Pubmedid: 28642818. Pmcid: PMC5477132.
• Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neurooncol. 2017 Jan.19(1):99-108. Pubmedid: 27576871. Pmcid: PMC5193026.
• Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Chavez J, Calzada O, Lansigan F, Nasheed H, Barta S, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. Am J Hematol. 2017 Feb.92(2):161-170. Pubmedid: 27880984. Pmcid: PMC5549936.
• Sam C, Desai P, Laber D, Patel A, Visweshwar N, Jaglal M. Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient. Transfus Med. 2017 Aug.27(4):300-302. Pubmedid: 28401611.
• Visweshwar N, Jaglal M, Booth C, Griffin P, Laber D. AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia. Ann Hematol. 2016 Oct.95(10):1747-1749. Pubmedid: 27449072. Pmcid: PMC4982880.
• Balakrishnan A, Ledford R, Jaglal M. Temozolomide-induced biliary ductopenia: a case report. J Med Case Rep. 2016 Feb.10:33. Pubmedid: 26846183. Pmcid: PMC4743416.
• Griffin PT, Jaglal M. Metastatic prostate cancer mimicking thrombotic thrombocytopenic purpura. Blood. 2015 Feb.125(8):1349. Pubmedid: 25853149.
• Dalia S, Price S, Forsyth P, Sokol L, Jaglal M. What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?. Leuk Lymphoma. 2015 Feb.56(2):500-502. Pubmedid: 24882264.
• Luria L, Nguyen J, Zhou J, Jaglal M, Sokol L, Messina JL, Coppola D, Zhang L. Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review. World J Gastroenterol. 2014 Sep.20(33):11894-11903. Pubmedid: 25206297. Pmcid: PMC4155383.
• Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske T, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct.124(15):2354-2361. Pubmedid: 25161267.
• Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L. Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years. Cancers (Basel). 2014 Nov.6(4):2275-2295. Pubmedid: 25405526. Pmcid: PMC4276966.
• Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr.99(4):450-456. Pubmedid: 24584873.
• Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr.38(4):443-446. Pubmedid: 24439565.

Title: Microbial metabolome is a predictor of TIL efficacy in metastatic melanoma.
Sponsor: Moffitt Cancer Center
PI: Jaglal, M.